Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use.
artificial tears
dry eye
non-invasive Keratograph break-up time
Keratograph
Ocular Surface Disease Index
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
02
2020
accepted:
17
03
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Artificial tears only provide transient relief for dry eye. To the best of our knowledge, this is the first study to objectively compare treatment with artificial tears with Keratograph 5M, which allows accurate and objective investigation of dry eye and artificial tear treatment. We aimed to evaluate whether a preservative-free combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan can improve dry eye using the new topographer, Keratograph 5M. This prospective longitudinal, single-arm interventional cohort study was performed at a tertiary referral center and involved 20 patients with dry eye (40 eyes). Preservative-free artificial tears were administered every 3 h. The participants underwent clinical and instrumental evaluations at baseline, 15, 30, 60, 90 and 120 min after instillation and 1 week and 1 month after treatment. Baseline values were considered as the controls. All patients were assessed with Keratograph 5M for non-invasive Keratograph first break-up time and non-invasive Keratograph average break-up time, conjunctival hyperemia, and tear meniscus height. Ocular surface staining with fluorescein was evaluated using the slit-lamp and fluorescein break-up time examinations, and the Ocular Surface Disease Index score was recorded for each patient. The signs and symptoms improved after 1 month of preservative-free 0.4% hyaluronic acid and 0.2% galactoxyloglucan treatment. There was a significant increase in the non-invasive Keratograph first break-up time and non-invasive Keratograph average break-up time at 15, 30, 60, and 90 min, and 1 week and 1 month (P < 0.05) and a decrease in hyperemia, corneal staining, and Ocular Surface Disease Index scores after 1 week and 1 month (P < 0.05). No treatment-related adverse event was observed. A combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan artificial tears seems effective for treating dry eye. Keratograph 5M can objectively detect these changes during the follow-up period.
Identifiants
pubmed: 32425501
doi: 10.2147/OPTH.S248949
pii: 248949
pmc: PMC7196196
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1153-1159Informations de copyright
© 2020 Molina-Solana et al.
Déclaration de conflit d'intérêts
IATA and RETICS OFTARED have sponsored the translation of this manuscript. AMG-H, JM-I, ER-d-l-R-F, and MC-M are members of RETICS OFTARED ‘RD16/0008/0010ʹ, financed by Instituto de Salud Carlos III, as part of the Plan Nacional I+D+i 2013–2016 and co-financed by the European Union (FEDER/FSE) “Una manera de hacer Europa.” None of the funding agencies played an active role in the study design and in the decision to submit this manuscript for publication, and they do not have ultimate authority over any of these activities. The authors report no other possible conflicts of interest in this work.
Références
Int J Pharm. 2010 Aug 16;395(1-2):122-31
pubmed: 20580791
Clin Ophthalmol. 2010 Sep 20;4:1035-41
pubmed: 20922039
Optom Vis Sci. 2015 Sep;92(9):e257-63
pubmed: 26154689
Semin Ophthalmol. 2018;33(5):643-650
pubmed: 29144869
Clin Ophthalmol. 2015 Jun 09;9:1029-31
pubmed: 26089634
J Ocul Pharmacol Ther. 2017 Oct;33(8):635-643
pubmed: 28846481
Cornea. 2015 Oct;34(10):1209-13
pubmed: 26266429
Cornea. 2003 Oct;22(7):640-50
pubmed: 14508260
Am J Ophthalmol. 2014 Apr;157(4):799-806
pubmed: 24388838
Eye Contact Lens. 2017 Nov;43(6):383-388
pubmed: 27243353
Curr Eye Res. 2018 Feb;43(2):155-162
pubmed: 29135324
Arch Ophthalmol. 2000 Sep;118(9):1264-8
pubmed: 10980773
Optom Vis Sci. 2015 Aug;92(8):892-9
pubmed: 26099055
Acta Ophthalmol. 2015 Mar;93(2):e135-9
pubmed: 25308575
Curr Eye Res. 2018 May;43(5):588-594
pubmed: 29388845
Cornea. 2015 Oct;34 Suppl 10:S48-52
pubmed: 26226477
Cornea. 2016 May;35(5):654-8
pubmed: 26989953
BMC Ophthalmol. 2018 Sep 5;18(1):237
pubmed: 30185156
Ophthalmic Res. 2014;51(3):146-52
pubmed: 24557328
Clin Ophthalmol. 2018 Mar 06;12:453-461
pubmed: 29563769